Optimising Analytical Methods to Guarantee Safe, High Quality, Consistent & Efficacious Gene Therapy Products

In the context of unprecedented gene therapy investment and clinical progress, with mounting regulatory scrutiny, Gene Therapy Analytical Development Europe will unite innovative biotech and pharma organisations to develop robust analytical tools to guarantee the consistency, quality, and safety of gene therapy products.

Whether you’re looking for specific characterisation, potency or infectivity approaches to improve your current analytical toolbox or if you’re seeking to understand how gene therapy analytics differ from other biologics you’ve worked on in the past, this focused, technical event will provide insights specifically on the unique analytical challenges posed by gene therapy vectors, delivered by ‘boots on the ground’ scientists grappling with these challenges first-hand.

Join 150+ analytical pioneers to discover the realities of working with tools like dPCR, AUC and HPLC, as well as how and where these tools can be most effective in process development, and what the European regulators expect in order to grant approval. Whether you’re working with AAV or lentiviral vectors, this is your opportunity to enhance your existing analytical methods and explore innovative new tools to support safe and effective gene therapy development.

Access the official event guide for more information.

World Class Speaker Faculty

Barbara Bonamassa

Quality Assessor & European Medicines Agency (EMA) Expert for ATMPs

Italian Medicines Agency (AIFA)

Matt Hankinson

Associate Director

Allergan

Roland Pach

Project Lead Analytical Technical

Roche

Lyndi Rice

Head of QC

BioMarin

Uditha DeAlwis

Executive Director

Sarepta Therapeutics

Santosh Khatwani

Associate Director Analytical Development

Sangamo

Robert Pletzanauer

Head of Process Analytics

Takeda

Connie Tsai

Senior Scientist Analytical Development

Novartis Gene Therapies

Other Events in the Gene Therapy Series